BioMarin Pharmaceutical | BMRN - Equity Capital And Reserves


BioMarin Pharmaceutical reported $6.21B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Bayer EUR 28.85B 2.9B Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
Insmed USD 704.85M 34.12M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Moderna USD 7.41B 1.24B Mar/2026
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 73.14B 1.43B Mar/2026
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
United Therapeutics USD 5.9B 1.2B Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026